Overview

MPC-004 for the Treatment of an Acute Gout Flare

Status:
Completed

Trial end date:
2007-10-01

Target enrollment:

Participant gender:

Summary

This study is a multicenter, randomized, double-blind, placebo-controlled, parallel group, dose-comparison to determine the efficacy and safety of a standard-dose of colchicine (4.8 mg) versus low-dose colchicine (1.8 mg) or placebo for acute gout flares.

Phase:

Phase 3

Details

Lead Sponsor:

Takeda

Treatments:

Colchicine